Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:KODNYSE:NUVBNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.87+0.5%$1.93$1.60▼$2.54$717.37M1.041.35 million shs1.57 million shsKODKodiak Sciences$3.63+0.3%$3.76$1.92▼$11.60$191.01M2.27349,278 shs205,700 shsNUVBNuvation Bio$2.02+2.3%$2.15$1.54▼$3.97$670.32M1.372.79 million shs7.90 million shsREPLReplimune Group$9.23-0.4%$8.87$6.44▼$17.00$714.59M0.63853,939 shs794,173 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+0.54%-3.11%-7.88%+2.19%-19.74%KODKodiak Sciences+0.28%-2.94%+5.52%+13.44%+37.50%NUVBNuvation Bio+3.07%+8.63%-12.77%+3.87%-33.93%REPLReplimune Group-0.43%-6.10%+10.54%-13.66%+8.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.5795 of 5 stars0.05.00.00.00.60.02.5KODKodiak Sciences4.238 of 5 stars3.04.00.04.62.53.30.0NUVBNuvation Bio3.4573 of 5 stars4.60.00.00.03.15.00.0REPLReplimune Group4.2839 of 5 stars3.63.00.04.51.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.00147.93% UpsideNUVBNuvation Bio 3.20Buy$7.17255.67% UpsideREPLReplimune Group 3.13Buy$20.83125.71% UpsideCurrent Analyst Ratings BreakdownLatest KOD, REPL, NUVB, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.13N/AN/A$2.90 per share0.64KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ANUVBNuvation Bio$7.87M87.12N/AN/A$1.37 per share1.47REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1314.3962.3342.1839.69%-0.07%-0.07%8/6/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)NUVBNuvation Bio-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/6/2025 (Estimated)Latest KOD, REPL, NUVB, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75KODKodiak SciencesN/A4.624.62NUVBNuvation BioN/A9.019.01REPLReplimune Group0.177.957.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%KODKodiak Sciences89.06%NUVBNuvation Bio61.67%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%KODKodiak Sciences45.90%NUVBNuvation Bio29.93%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million359.07 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableNUVBNuvation Bio60340.26 million238.42 millionOptionableREPLReplimune Group21077.09 million70.30 millionOptionableKOD, REPL, NUVB, and CRON HeadlinesRecent News About These CompaniesCantor Fitzgerald Begins Coverage on Replimune Group (NASDAQ:REPL)June 22 at 1:13 AM | americanbankingnews.comCantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight RecommendationJune 21 at 12:04 AM | msn.comReplimune Group (NASDAQ:REPL) Coverage Initiated at Cantor FitzgeraldJune 20, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DEJune 14, 2025 | marketbeat.comReplimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 PlanJune 6, 2025 | quiverquant.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comWellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)June 3, 2025 | marketbeat.comPiper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock PriceJune 2, 2025 | marketbeat.comReplimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2025 | globenewswire.comTwo Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)June 1, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsJune 1, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?May 31, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's WhyMay 30, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLCMay 30, 2025 | marketbeat.comReplimune to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comHC Wainwright Estimates Replimune Group Q3 EarningsMay 27, 2025 | marketbeat.comLeerink Partnrs Estimates Replimune Group Q1 EarningsMay 27, 2025 | marketbeat.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26, 2025 | investing.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LPMay 25, 2025 | marketbeat.comMillennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingPayment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?By Gabriel Osorio-Mazilli | June 23, 2025View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?KOD, REPL, NUVB, and CRON Company DescriptionsCronos Group NASDAQ:CRON$1.87 +0.01 (+0.54%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.48%) As of 06/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Kodiak Sciences NASDAQ:KOD$3.63 +0.01 (+0.28%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.63 0.00 (0.00%) As of 06/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Nuvation Bio NYSE:NUVB$2.02 +0.05 (+2.28%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$2.04 +0.02 (+1.24%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Replimune Group NASDAQ:REPL$9.23 -0.04 (-0.43%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$9.24 +0.01 (+0.16%) As of 06/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
